These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24666252)

  • 61. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
    Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
    Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification.
    Brum da Silva Nunes V; Kehl Dias C; Nathali Scholl J; Nedel Sant'Ana A; de Fraga Dias A; Granero Farias M; Alegretti AP; Sosnoski M; Esteves Daudt L; Bohns Michalowski M; Oliveira Battastini AM; Paz AA; Figueiró F
    Discov Oncol; 2022 Dec; 13(1):143. PubMed ID: 36581667
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A novel immune prognostic model of non-M3 acute myeloid leukemia.
    Ding H; Feng Y; Xu J; Lin Z; Huang J; Wang F; Luo H; Gao Y; Zhai X; Wang X; Zhang L; Niu T; Zheng Y
    Am J Transl Res; 2022; 14(8):5308-5325. PubMed ID: 36105048
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.
    Leotta S; Condorelli A; Sciortino R; Milone GA; Bellofiore C; Garibaldi B; Schininà G; Spadaro A; Cupri A; Milone G
    J Clin Med; 2022 Jan; 11(1):. PubMed ID: 35011994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Kunadt D; Stölzel F
    Cancer Manag Res; 2021; 13():7411-7427. PubMed ID: 34594134
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
    Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
    Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Extracellular Adenine Nucleotides and Adenosine Modulate the Growth and Survival of THP-1 Leukemia Cells.
    Puchałowicz K; Tarnowski M; Tkacz M; Chlubek D; Kłos P; Dziedziejko V
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580317
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
    Mardiana S; Gill S
    Front Oncol; 2020; 10():697. PubMed ID: 32435621
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The TGF-b/SOX4 axis and ROS-driven autophagy co-mediate CD39 expression in regulatory T-cells.
    Gerner MC; Ziegler LS; Schmidt RLJ; Krenn M; Zimprich F; Uyanik-Ünal K; Konstantopoulou V; Derdak S; Del Favero G; Schwarzinger I; Boztug K; Schmetterer KG
    FASEB J; 2020 Jun; 34(6):8367-8384. PubMed ID: 32319705
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.
    Rovatti PE; Gambacorta V; Lorentino F; Ciceri F; Vago L
    Front Immunol; 2020; 11():147. PubMed ID: 32158444
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.
    Willig JB; Vianna DRB; Beckenkamp A; Beckenkamp LR; Sévigny J; Wink MR; Buffon A; Pilger DA
    Purinergic Signal; 2020 Mar; 16(1):29-40. PubMed ID: 31955347
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.
    Bernasconi P; Borsani O
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31881776
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.
    Vaisitti T; Arruga F; Guerra G; Deaglio S
    Front Immunol; 2019; 10():2301. PubMed ID: 31636635
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment.
    Bernasconi P; Borsani O
    J Oncol; 2019; 2019():8323592. PubMed ID: 31485227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
    Knaus HA; Kanakry CG; Luznik L; Gojo I
    Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis.
    Dulphy N; Henry G; Hemon P; Khaznadar Z; Dombret H; Boissel N; Bensussan A; Toubert A
    Br J Haematol; 2014 Jun; 165(5):722-5. PubMed ID: 24666252
    [No Abstract]   [Full Text] [Related]  

  • 77. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
    Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
    Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.
    Boer MC; van Meijgaarden KE; Bastid J; Ottenhoff TH; Joosten SA
    Eur J Immunol; 2013 Jul; 43(7):1925-32. PubMed ID: 23606272
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
    Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
    Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The NOTCH1/CD39 axis: a Treg trip-switch for GvHD.
    Del Papa B; Pierini A; Sportoletti P; Baldoni S; Cecchini D; Rosati E; Dorillo E; Aureli P; Zei T; Iacucci Ostini R; Ruggeri L; Carotti A; Velardi A; Negrin R; Martelli MF; Falzetti F; Di Ianni M
    Leukemia; 2016 Sep; 30(9):1931-4. PubMed ID: 27125307
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.